Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Truth

<< Previous

Bullboard Posts

Next >>

Comment by Captainblkon Mar 01, 2021 9:00pm

333 Views

Post# 32691922

RE:Truth

Stockdeals wrote: The truth is out there, I'm not going to do your DD for you Dig deeper!

so let me get this straight:

you show up on a stock out of nowhere with supposedly no vested interest and never posting here before
you post nothing regarding any sort of arguement for or against
you post in a way that pretends that you want to help or warn people by inferring or trying to illicit FUD
and then you say hey do your own DD

do you want to help people or do you not want to help people? either post some contructive critiques for or against or take your "insight" elsewhere. several here have been in this so long its nothing but green on the way up

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China